Effect analysis of anlotinib combined with immune checkpoint inhibitors in the treatment of advanced lung cancer
Objective To investigate the efficacy and safety of anlotinib combined with immune checkpoint inhibitors for patients with advanced lung cancer.Methods Clinical data of 118 patients with lung cancer were retrospectively analyzed.According to different treatment methods,all patients were divided into single-agent group(56 cases)and combined group(62 cases).The single-agent group was treated with oral antirotinib,and the combined group was treated with antirotinib combined with immune checkpoint inhibitors.The short-term efficacy,progression free survival(PFS),PFS of patients with Charlson comorbidity index of 0-1 points and patients in first or second-line treatment,and occurrence of adverse reactions were compared between the two groups.Results In the single-agent group,there were no complete response(CR),partial response(PR)in 4 cases(7.1%),stable disease(SD)in 41 cases(73.2%),and progressive disease(PD)in 11 cases(19.6%).In the combined group,there were 17 cases(27.4%)of CR,37 cases(59.7%)of SD and 8 cases(12.9%)of PD.The objective response rate(ORR)of 27.4%in the combined group was higher than 7.1%in the single-agent group,and the difference was statistically significant(P<0.05);the disease control rate(DCR)of 87.1%was slightly higher than 80.4%in the single-agent group,but the difference was not statistically significant(P>0.05).The median PFS in the combined group was 4.1 months,which was longer than 3.0 months in the single-agent group(P<0.05).The median PFS of patients with Charlson comorbidity index of 0-1 points and patients in first or second-line treatment in combined group were 5.0 and 7.0 months,which were longer than 3.8 and 4.4 months in single-agent group,and the difference was statistically significant(P<0.05).In the single-agent group,the incidence of hypertension was 19.6%(11/56),the incidence of fatigue was 14.3%(8/56),the incidence of urinary protein was 7.1%(4/56)and the incidence of endocrine abnormality was 5.3%(3/56).In the combined group,the incidence of hypertension was 16.1%(10/62),the incidence of fatigue was 16.1%(10/62),the incidence of endocrine abnormality was 11.3%(7/62),the incidence of liver function abnormality was 9.7%(6/62)and the incidence of immune pneumonia was 4.8%(3/62).There were 2 patients with grade 3 hypertension in the single-agent group,3 patients with grade 3 hypertension in the combined group,and the rest were grade 1-2 hypertension.All patients were improved after withdrawal of medication and treatment.Conclusion Allotinib combined with immune checkpoint inhibitors is safe in the treatment of advanced lung cancer.However,the more advanced the treatment,the worse the therapeutic effect.Combination therapy has an advantage in prolonging PFS for patients with Charlson comorbidity index of 0-1 points and patients in first or second-line treatment.
万方数据
维普
